Clinical Physiology of Circulation

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


a:2:{s:4:"TEXT";s:150:"The development of endovascular methods of photodynamic therapy in rabbits with experimental atherosclerosis and arterial stenosis in places stents ";s:4:"TYPE";s:4:"HTML";}

Authors: L.A. Bockeria 1 , A.Yu. Gorodkov 1 , E.M. Tararak 2 , S.G. Kuz’min 3 , V.B. Loshchenov 4 , P.I. Sharaev 1 , A.A. Korаtaeva 2 , V.I. Makarov 4 , I.M. Krestinich 1 , Sh.T. Zhorzholiani 1 , Yu.M. Tsygankov 1

Company:
1 A.N. Bakoulev Scientific Center for Cardiovascular Surgery, Rublevskoe shosse, 135, Moscow, 121552, Russian Federation;
2 Russian Cardiology Research-and-Production Complex Ministry of Health of the RF, ul. Tret’ya Cherepkovskaya, 15a, Moscow, 121552, Russian Federation;
3 Research Institute of Organic Intermediates and Dyes, ul. Bol’shaya Sadovaya, 1, korpus 4, Moscow, 123995, Russian Federation;
4 A.M. Prokhorov General Physics Institute, ul. Vavilova, 38, Moscow, 119991, Russian Federation

E-mail: Сведения доступны для зарегистрированных пользователей.

Link: Clinical Physiology of Blood Circulaiton. 2015; (): -

Quote as: Bockeria L.A., Gorodkov A.Yu., Tararak E.M., Kuz’min S.G., Loshchenov V.B., Sharaev P.I., Korаtaeva A.A., Makarov V.I., Krestinich I.M., Zhorzholiani Sh.T., Tsygankov Yu.M.. The development of endovascular methods of photodynamic therapy in rabbits with experimental atherosclerosis and arterial stenosis in places stents. Klinicheskaya Fiziologiya Krovoobrashcheniya (Clinical Physiology of Circulation, Russian journal). 2015; 1: 53-63 (in Russ.)

Download
Full text:  

Abstract

Objective – to explore the possibility of sclerotic and proliferative processes inhibition at the sites of a vascular stent installation using the method of photodynamic therapy (PDT) in the experiment.

Material and methods . Ten rabbits, five of which were on hypercholesterol diet, a stent was installed in the thoracic aorta. The three rabbits during stenting, at 2 and 4 months after stenting were undergone to repeated sessions of intravascular PDT with Photosens® in the field of stents. The secretory phospholipase A2-IIA (secFlA2-IIA) concentration and activity and blood lipid levels were measured, the control aortography and intravascular ultrasound (IVUS) were performed. Morphology of the aortic wall at the site of stent implantation and nearby was studied.

Results . Studies have revealed multiple lipid build-up of cholesterol, low-density lipoprotein, triglycerides and atherogenic factor in the group of rabbits with hypercholesterol diet. Analysis secFlA2-IIA contained in the blood of rabbits to stenting and on the 5th day after the procedure showed that the mean concentration secFlA2-IIA has increased, but the correlation between elevated levels and increased activity secFlA2-IIA has been identified. When aortography from several rabbits revealed some rough contours of the aorta, but stenosis (40%) out of the stent revealed only one rabbit, is on hypercholesterol diet, referred to the high-risk group in terms of concentration and activity secFlA2-IIA. According to IVUS performed in 6 rabbits constrictive process in stented and adjacent to the stent portions of the aorta did not develop. Increasingly sclerotic and proliferative changes in the aortas were observed in animals related to an increased risk in terms of concentration and activity secFlA2-IIA. In other parts of the aorta, not exposed to PDT, the degree of sclerotic changes corresponded to the duration of hypercholesterol diet.

Conclusion . Morphological study has shown that the severity of sclerotic and proliferative changes in the rabbit aorta is proportional to the duration of hypercholesterol diet, while the concentration and activity of secretory phospholipase A2-IIA can serve as indicators of the intensity of atherogenesis. Repeated sessions of PDT reduce the intensity of atherogenesis at the sites of stent placement.

References

  1. Mallat Z., Benessiano J., Simon T., Ederhy S., Sebella- Arguelles C., Cohen A. et al. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: The EPIC-NORFOLK Study. Arterioscler. Thromb. Vasc. Biol. 2007; 27: 1177–83.
  2. Восканьянц А.Н. Роль апоптоза и пролиферации клеток сосудистой стенки в атерогенезе: Автореф. дис. … канд. биол. наук. СПб.; 2004.
  3. Климов А.Н., Нагорнев В.А., Денисенко А.Д., Константинов В.О. Аутоиммунная теория патогенеза атеросклероза и новые пути его лечения. Вест. Рос. АМН. 2003; 12: 29–34.
  4. Denisenko A.D., Makovejchuk E.G., Vinigradov A.G. Autoantibidies against oxidized low density lipoproteins and lipoprotein-antibidy autoimmune complexes in human atherosclerosis. Eur. J. Lab. Med. 1996; 4: 85–90.
  5. Лобзин Ю.В., Рудакова А.В. Роль инфекционно-воспалительного фактора в развитии атеросклероза. Мед. акад. журн. 2003; 3 (2): 80–9.
  6. Нагорнев В.А., Пигаревский П.В., Восканьянц А.Н., Яковлева О.А. Современные взгляды на проблему патогенеза атеросклероза с позиций инфекционной патологии. Вест. Рос. АМН. 2002; 12: 9–15.
  7. Mahony J.B., Coombes B.K. Chlamydia pneumoniae and atherosclerosis: dose the evidence support a causal or contributory role? FEMS Microb. Lett. 2001; 197: 1–9.
  8. Нагорнев В.А., Яковлева О.А., Рабинович В.С. Атерогенез и воспаление. Мед. акад. журн. 2001; 1 (1): 36–43.
  9. Hansson G.K., Libby P. (eds). Immune response in atherosclerosis. Immune functions of the vessel wall. Harwood Acad. Publ.; 1996: 143–57.
  10. Нагорнев В.А., Кетлинский С.А. Клеточно-молекулярные механизмы становления и развития атерогенеза: CD40-CD40L иммунорегуляторный сигнал. Бюл. экспер. биол. 1999; 10: 364–71.
  11. Нагорнев В.А., Восканьянц А.Н. Атерогенез как иммуно- воспалительный процесс. Вест. Рос. АМН. 2004; 7: 3–10.
  12. Mach F., Schonbeck U., Libby P. CD40 signaling in vascular cells: A key role in atherosclerosis? Atherosclerosis. 1998; 137 (1): 89–95.
  13. Xu Q. Role of heat shock proteins in atherosclerosis. Arterioscler. Thromb. Vase. Biol. 2002; 22: 1547–59.
  14. Schering A., Menschikowsky M., Mueller E., Jaross W. Analysis of secretory group II phospholipase A2 expression in human aortic tissue in dependence on the degree of atherosclerosis. Atherosclerosis. 1999; 144 (1): 73–8.
  15. Boekholdt S.M., Keller T.T., Wareham N.J., Luben R., Bingham S.A., Day N.E. et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: The EPICNorfolk Prospective Population Study. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 839–46.
  16. Коротаева А.А. Секреторная фосфолипаза А2 группы IIА в сыворотке крови больных после коронарной ангиопластики: регуляция липидами и липопротеидами: Автореф. дис. … д-ра биол. наук. М.; 2009.
  17. Mallat Z., Steg P.G., Benessiano J., Tanguy M.L., Fox K.A., Collet J.P. et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J. Am. Coll. Cardiol. 2005; 46: 1249–57.
  18. Возовиков И.Н., Андреева Е.Р., Янцен Е.С., Кузьмин С.Г., Тарарак Э.М. Возможности использования фотодинамической терапии для лечения и профилактики сердечно-сосудистых заболеваний. Кардиологический вестник. 2006; 13.
  19. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler. Thromb. Vase. Biol. 2001; 21: 1876–90.
  20. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135–43.
  21. Wick G., Xu Q. Atherosclerosis — an autoimmune disease. Exp. Gerontology. 1999; 34: 559–66.

 If you found mistakes, select text and press Alt+A